1、研究者对接受去势治疗和抗PD-1治疗的mCSPC患者的转移灶进行单细胞RNA测序分析,鉴定出多个转移灶上的肿瘤和免疫细胞亚群; 2、研究者进一步揭示了治疗引起的这些亚群的动态变化及其与临床结果的相关性 2023年11月02日,哥伦比亚大学爱尔文医学中心的研究人员在Cancer Cell期刊发表了题为:Anti-PD-1 immunotherapy with ...
Anti-PD-1 immunotherapyImmune checkpoint inhibitorsNivolumabPembrolizumabImmunotherapy with immune checkpoint inhibitors, such as anti-PD-1 drugs, is an area in increasing development for its efficacy and advantages in the treatment of advanced metastatic melanoma. In fact, immunotherapy has been the ...
总的来说，研究对转移性肾透明细胞癌在anti-PD-1治疗前和后的基因组和肿瘤免疫微环境的特征进行了详细的描绘，揭示出患者对anti-PD-1有响应的决定性因素，或对ccRCC病人的精准医疗具有参考价值。原文链接：https://doi.org/10.1016/j.ccell.2021.10.001 参考文献 1. Fridman, W.H., Zitvogel, L., Saute...
3. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144-153. 4. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW et al. D...
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case seriesLung cancer is one of the most common cancers in the world and it is the leading cause of cancer-related deaths, among men and women, in the United States. In advanced non-...
2021年5月26日讯/生物谷/BIOON/---近日,澳门科技大学在Gut杂志上发表了题为"Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti- PD-1/PD- L1) immunotherapy"的研究性文...
抗PD-1联合抗CTLA-4抗体介导的免疫治疗对黑色素瘤、肾细胞癌和非小细胞肺癌具有显著疗效。然而,它们也常常伴随严重免疫反应以及一些副作用。结肠炎是最常见和严重的副作用之一。 目前,抑制这些免疫相关不良反应的方法是停止使用抗PD -1和抗CTLA-4治疗,并开始类固醇疗程。在严重的病例中,患者被给予抗TNF抗体以减少不...
ImmunotherapyPD-L1/PD-1Immune checkpoint inhibitorTumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. Ovarian cancer is the leading cause of mortality from gynecological malignancies, and...
Owing to a lack of response to the anti-PD1 therapy for most cancer patients, we develop a network approach to infer genes, pathways, and potential therapeutic combinations that are associated with tumor response to anti-PD1. Here, our prediction identif
(29:39) Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase 1x 0:00 / 0:00 Subscribe to Podcast Key Points Question Is a universal cutoff value to define high tumor mutational burden (TMB) associated with tumor response to cancer immunotherapy?